Vericel Co. (NASDAQ:VCEL) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its stake in shares of Vericel Co. (NASDAQ:VCEL) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 139,736 shares of the biotechnology company’s stock after selling 718 shares during the period. Rhumbline Advisers owned 0.28% of Vericel worth $7,673,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in shares of Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock worth $24,837,000 after acquiring an additional 400,667 shares during the period. Stifel Financial Corp grew its holdings in shares of Vericel by 40.0% in the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company’s stock valued at $1,186,000 after purchasing an additional 8,020 shares during the period. Geode Capital Management LLC increased its position in Vericel by 0.8% during the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock worth $48,768,000 after purchasing an additional 9,613 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in Vericel by 0.8% during the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company’s stock worth $1,312,000 after purchasing an additional 200 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Vericel in the 3rd quarter valued at about $563,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on VCEL shares. Canaccord Genuity Group raised their price target on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Truist Financial lifted their target price on Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. BTIG Research increased their price target on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $63.14.

Vericel Trading Up 0.4 %

Shares of NASDAQ VCEL opened at $52.52 on Wednesday. The stock has a market capitalization of $2.59 billion, a PE ratio of 875.48 and a beta of 1.72. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The stock has a fifty day simple moving average of $57.48 and a 200-day simple moving average of $51.75.

Insider Buying and Selling at Vericel

In other Vericel news, Director Paul K. Wotton sold 2,600 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total transaction of $152,672.00. Following the sale, the director now directly owns 27,402 shares in the company, valued at $1,609,045.44. This represents a 8.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares of the company’s stock, valued at $1,662,187.50. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,100 shares of company stock valued at $1,206,072 in the last three months. 5.20% of the stock is owned by corporate insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.